Tafluprost in the treatment of glaucoma

Expert Review of Ophthalmology

Volumn 7, Issue 5, 2012, Pages

  Kaplowitz, Kevin ^a   Tsai, James C ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glaucoma; prostanoid; tafluprost

Indexed keywords

EID: 84868266984     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.12.44     Document Type: Review

References (63)

1. Quigley HA. Glaucoma. Lancet 377(9774), 1367-1377 (2011).
2. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120(6), 701-713 (2002). (Pubitemid 34620348)
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120(10), 1268-1279 (2002). (Pubitemid 36105431)
4. Group CN-TGS. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126(4), 487-497 (1998).
5. Allingham RR, Shields MB. Shields' Textbook Of Glaucoma. Lippincott Willliams & Wilkins, PA, USA, (2011).
6. Nordmann JP, Mertz B, Yannoulis NC, Schwenninger C, Kapik B, Shams N; Unoprostone Monotherapy Study Group-EU. A double-masked randomized comparison of the effcacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am. J. Ophthalmol. 133(1), 1-10 (2002). (Pubitemid 34076498)
7. Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc. Drug Rev. 24(1), 1-10 (2006). (Pubitemid 46696782)
8. Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J. Glaucoma 18(9), 652-657 (2009).
9. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 112(7), 1177-1185 (2005). (Pubitemid 40916921)
10. Stamer WD, Huang Y, Seftor RE, Svensson SS, Snyder RW, Regan JW. Cultured human trabecular meshwork cells express functional a 2A adrenergic receptors. Invest. Ophthalmol. Vis. Sci. 37(12), 2426-2433 (1996). (Pubitemid 26391280)
11. Einarson TR, Kulin NA, Tingey D, Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin. Ther. 22(12), 1502-1515 (2000). (Pubitemid 32056088)
12. David R. Changing therapeutic paradigms in glaucoma management. Expert Opin. Investig Drugs 7(7), 1063-1086 (1998). (Pubitemid 28323092)
13. Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv. Ophthalmol. 41(Suppl. 2), S61-S68 (1997). (Pubitemid 27154526)
14. Pozarowska D. Safety and tolerability of tafuprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin. Ophthalmol. 4, 1229-1236 (2010).
15. Nakajima T, Matsugi T, Goto W et al New fuoroprostaglandin F(2o¢) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypo tensive agents. Biol. Pharm. Bull. 26(12), 1691-1695 (2003). (Pubitemid 39663527)
16. Takagi Y, Nakajima T, Shimazaki A et al. Pharmacological characteristics of AFP-168 (tafuprost), a new prostanoid FP-receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 78 (4), 767-776 (2004). (Pubitemid 38252953)
17. Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α. Curr. Eye Res. 1(4), 205-209 (1981). (Pubitemid 11025673)
18. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2α-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outfow by prostaglandin F2α. Arch. Ophthalmol. 105 (8), 1112-1116 (1987). (Pubitemid 17136391)
19. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outfow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48(5), 707-716 (1989). (Pubitemid 19143452)
20. Stjernschantz JW. From PGF(2α)-isopropyl ester to latanoprost: A review of the development of xalatan: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42(6), 1134-1145 (2001). (Pubitemid 32381949)
21. Akaishi T, Kurashima H, Odani-Kawabata N, Ishida N, Nakamura M. Effects of repeated administrations of tafuprost, latanoprost, and travoprost on optic nerve head blood fow in conscious normal rabbits. J. Ocul. Pharmacol. Ther. 26(2), 181-186 (2010).
22. Mayama C, Ishii K, Saeki T, Ota T, Tomidokoro A, Araie M. Effects of topical phenylephrine and tafuprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 51(8), 4117-4124 (2010).
23. Dong Y, Watabe H, Su G, Ishikawa H, Sato N, Yoshitomi T. Relaxing effect and mechanism of tafuprost on isolated rabbit ciliary arteries. Exp. Eye Res. 87(3), 251-256 (2008).
24. Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin F(2a) analogues on endothelin-1-induced impairment of rabbit ocular blood fow: comparison among tafuprost, travoprost, and latanoprost. Exp. Eye Res. 91(6), 853-859 (2010).
25. Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafuprost, following ocular administration to rats. Drug Metab. Dispos. 37(8), 1622-1634 (2009).
26. Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, effcacy and safety profles of preserved and preservative-free tafuprost in healthy volunteers. Acta Ophthalmol. Suppl. (Oxf.). 242, 7-13 (2008).
27. Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest. Ophthalmol. Vis. Sci. 25(12), 1453-1457 (1984). (Pubitemid 15191102)
28. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafuprost. Ophthalmic Res. 41(2), 118-122 (2009).
29. Januleviciene I, Derkac I, Grybauskiene L, Paulauskaite R, Gromnickaite R, Kuzmiene L. Effects of preservative-free tafuprost on tear flm osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin. Ophthalmol. 6, 103-109 (2012).
30. Ota T, Murata H, Sugimoto E, Aihara M, Araie M. Prostaglandin analogues and mouse intraocular pressure: effects of tafuprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest. Ophthalmol. Vis. Sci. 46(6), 2006-2011 (2005).
31. Kurashima H, Asai Y, Aihara M, Ishida N, Nakamura M, Araie M. Ocular hypotensive effect of tafuprost in latanoprost low-responder cynomolgus monkeys. J. Glaucoma 21 (2), 123-128 (2012).
32. Thygesen J. In search of improved prostaglandin treatment for glaucoma. Acta Ophthalmol. Suppl. (Oxf.). 242, 5-6 (2008).
33. Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fuoroprostaglandin-receptor agonists tafuprost and latanoprost in healthy males. J. Ocul. Pharmacol. Ther. 23(4), 359-365 (2007). (Pubitemid 350195060)
34. Sutton A, Gouws P, Ropo A. Tafuprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int. J. Clin. Pharmacol Ther. 46(8), 400-406 (2008).
35. Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafuprost compared with latanoprost. J. Ocul. Pharmacol. Ther. 26(1), 97-104 (2010).
36. Uusitalo H, Pillunat LE, Ropo A; Phase III Study Investigators. Effcacy and safety of tafuprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked Phase III study. Acta Ophthalmol. 88(1), 12-19 (2010).
37. Chabi A, Varma R, Tsai JC et al. Randomized clinical trial of the effcacy and safety of preservative-free tafuprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 153 (6), 1187-1196 (2012).
38. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Effcacy and safety levels of preserved and preservative-free tafuprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol. Suppl. (Oxf.). 242, 14-19 (2008).
39. Aihara M. Clinical appraisal of tafuprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin. Ophthalmol. 4, 163-170 (2010).
40. Milla E, Stirbu O, Rey A et al. Spanish multicenter tafuprost tolerability study. Br. J. Ophthalmol. 96(6), 826-831 (2012).
41. Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering effcacy and tolerability of preservative-free tafuprost 0.0015% among patients with ocular hypertension or glaucoma. Curr. Med. Res. Opin. 26(8), 1905-1913 (2010).
42. Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering effcacy and safety of travoprost 0.004% compared with tafuprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 4, 1459-1463 (2010).
43. Mochizuki H, Itakura H, Yokoyama T, Takamatsu M, Kiuchi Y. Twenty-four-hour ocular hypotensive effects of 0.0015% tafuprost and 0.005% latanoprost in healthy subjects. Jpn. J. Ophthalmol. 54(4), 286-290 (2010).
44. Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafuprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv. Ther. 28(7), 575-585 (2011).
45. Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Effcacy and safety of tafuprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn. J. Ophthalmol. 55(6), 605-613 (2011).
46. Stewart WC, Garrison PM. β-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch. Intern. Med. 158(3), 221-226 (1998). (Pubitemid 28123884)
47. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol. 55(1), 22-27 (2011).
48. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal. Plast. Reconstr. Surg. 24(4), 302-307 (2008).
49. Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. In vitro study of antiadipogenic profle of latanoprost, travoprost, bimatoprost, and tafuprost in human orbital preadiopocytes. J. Ocul. Pharmacol. Ther. 28(2), 146-152 (2012).
50. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv. Ophthalmol. 47(Suppl. 1), S219 (2002).
51. Markomichelakis NN, Kostakou A, Halkiadakis I, Chalkidou S, Papakonstantinou D, Georgopoulos G. Effcacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 247(6), 775-780 (2009).
52. Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br. J. Ophthalmol. 95(6), 869-875 (2011).
53. Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafuprost. Clin. Ophthalmol. 5, 623-631 (2011).
54. Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am. J. Ophthalmol. 103 (2), 188-193 (1987). (Pubitemid 17005483)
55. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: A systematic classifcation. J. Glaucoma 12(5), 393-398 (2003). (Pubitemid 37237370)
56. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br. J. Ophthalmol. 86(4), 418-423 (2002). (Pubitemid 34293291)
57. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 21(3), 167-177 (2007). (Pubitemid 46827850)
58. Stamer WD, Acott TS. Current understanding of conventional outfow dysfunction in glaucoma. Curr. Opin. Ophthalmol. 23(2), 135-143 (2012).
59. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch. Ophthalmol. 126(3), 309-315 (2008). (Pubitemid 351398453)
60. Williams RD, Novack GD, van Haarlem T, Kopczynski C; AR-12286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am. J. Ophthalmol. 152 (5), 834-841.e1 (2011).
61. Lagrèze WA, Knörle R, Bach M, Feuerstein TJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. Ophthalmol. Vis. Sci. 39(6), 1063-1066 (1998). (Pubitemid 28196695)
62. Pellegrini J W, Lipton SA. Delayed administration of memantine prevents N-methyl-d-aspartate receptor-mediated neurotoxicity. Ann. Neurol. 33(4), 403-407 (1993). (Pubitemid 23103976)
63. Osborne NN. Recent clinical fndings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 87(4), 450-454 (2009).